Review Article

Noncoding RNAs Act as Tumor-Derived Molecular Components in Inducing Premetastatic Niche Formation

Zhedong Zhang1, Jiao Qiao2, Dafang Zhang1, Weihua Zhu1, Jiye Zhu1, Xisheng Leng1, and Shu Li1

1Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing, 100044, China
2Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, 250021, China

Correspondence should be addressed to Shu Li; lishu@pkuph.edu.cn

Received 5 March 2019; Revised 4 May 2019; Accepted 27 May 2019; Published 12 June 2019

Copyright © 2019 Zhedong Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cancer metastasis has been demonstrated as it is the culmination of a cascade of priming steps. Increasing evidence has shown that tumor-derived molecular components (TDMCs) are known as extra cellular vesicle and nonvesicle factors and serve as versatile intercellular communication vehicles which can mediate signaling in the tumor microenvironment while creating the premetastatic niche. Noncoding RNAs (ncRNAs) as one of the TDMCs have been proved in participating in the formation of the premetastatic niche. Understanding the premetastatic niche formation mechanisms through TDMCs, especially ncRNAs may open a new avenue for cancer metastasis therapeutic strategies. In this review, recent findings regarding ncRNAs function were summarized, and then the interaction with the premetastatic niche formation was studied, which highlight the potential of using ncRNAs for cancer diagnosis and therapeutic effect.

1. Introduction

Increasing tumor patients pass away eventually owing to tumor metastatic progression every year, even though significant advancements have been achieved in cancer therapies [1]. Therefore, it emphasizes the important goal of cancer research efforts to identify the pivotal molecular and cellular components in every step of tumor metastasis to develop new strategy for prevention and control of tumor metastasis. About 100 years ago, “seed and soil” hypothesis was originally proposed by Stephen Paget [2] which indicated that metastatic tumor cell “seed” chose the fertile “soil” to colonization. Under numerous efforts of research groups, it is now widely accepted that primary tumors prior modulate the local microenvironment of distant organs in preparation for tumor cell colonization even before their arrival. The microenvironment is termed the premetastatic niche with a series changes including immunosuppression, inflammation, lymphangiogenesis, organotropism, angiogenesis, and vascular permeability [3], which is crucial for the development of metastasis and has attracted more and more attention in the last several years [4].

TDMCs, one of the primary tumor-secreted molecules can be divided into nonvesicle tumor-derived secreted factors (TDSFs) and tumor-derived secreted extracellular vesicles (EVs) and carry diverse molecular components, such as proteins, lipids, RNA, and DNA molecules [5]. They have the functions of recruiting BMDCs, making the immune cells heterogeneity, altering the vasculature, and reprogramming the stromal cells and metabolic progress [6]. Studies have shown that ncRNAs are involved in regulating tumor transcription, invasion, and metastasis, etc., and may control cancer-related genes by acting on proteins [7]. The expression of ncRNAs can be used to reflect the origin, grade, and other pathological constants of tumors and provide a method for the diagnosis and prognosis. In recent years, ncRNAs, as a new intercellular communication mechanism of TDMCs, have been established as an important part of premetastatic niche induction [8]. These new advances can indicate new direction to guide future research and better illustrate the
potential mechanisms of tumor metastasis to design more effective diagnosis and treatment strategies to fight cancer. Here we focus on the most recent findings on the ncRNAs and their underlying induced mechanisms of the premetastatic niche formation.

2. NcRNAs as a Sort of TDMCs

In human genome sequence, only 2% of capacity is mRNA which can encode protein [9]. ncRNAs, known as non-messenger refer to the RNAs without protein encoding function due to the lack of an open reading frame, and they are often transcribed from the complementary strand of protein encoding genes [10]. According to the length, ncRNAs are divided into long ncRNAs (lncRNAs) and short ncRNAs (<200nt), and short ncRNAs include microRNAs (miRNAs) and PIWI-interacting RNAs (piRNAs). Based on the position, ncRNAs can be divided into nonvesicle and extracellular vesicle sort. With the development of extensively parallel sequencing technology and high-resolution microarrays, ncRNAs especially lncRNAs, miRNAs, and circRNAs have caught extended attentions. Massive lines of evidence suggested that ncRNAs are not only involved in life activities but also closely related to tumor cell differentiation, proliferation, migration, invasion, and infiltration [8, 11].

When ncRNAs function as one category of TDMCs, they mainly exist in the EVs and the minority of them are free [12]. EVs carry a distinctive repertoire of lncRNAs and short ncRNAs [13, 14]. What is more, packaging RNA into the EVs is also a selective progress [15]. EVs can transfer special sorts of RNAs from donor to recipient cells under pathological and physiological conditions [16] (Figure 1).

3. NcRNAs: A Key to the Formation of the Premetastatic Niche

Previous research has found primary tumor-derived vesicles contribute to the formation of the premetastatic niche [17]. Exosomes secreted by different cell types contain different RNAs and proteins that germinate from the primary tumor cells and enter the bloodstream, which may help the cancer change the metastatic microenvironment and invade new organs [18].

3.1. MiRNAs. Increasing angiogenesis and vascular permeability are essential for tumor development and metastasis, and tumor-derived EV miRNAs promote this progress by affecting endothelia cells [19, 20]. In the premetastasis niche, metastatic breast cancer cells secret EV-encapsulated miR-105 to destroy the vascular barriers by downregulating cellular endothelial tight junction protein zonula occludens 1 (ZO-1), which induces vascular leakiness in distant organs to promote metastasis [21]. Brain metastatic cancer cells-derived EVs of breast cancer contain miR-181c, which modulate the actin...
dynamics by the downregulation of phosphoinositide dependent kinase 1 (PDK1) in brain endothelial cells to trigger blood brain barrier (BBB) destruction and facilitate cancer cells migration [22]. Distant lung fibroblast derived miR-30s stabilize pulmonary vessels in premetastatic lungs, the low expression of miR-30s could directly target the skp2 and promote pulmonary vascular destabilization via activating of matrix metalloproteinase 9 (MMP9) [23]. MiR-9, packaged in the SK23 melanoma cell-derived microvesicles (MVs) and delivered to the endothelial cells directly target the negative regulator suppressor of cytokine signaling 5 (SOCS5) and activating JAK-STAT signaling pathway to promote endothelial cell migration and tumor angiogenesis [24]. Exosomal miR-92a, derived from the leukemia cell line K562, has also shown the same function [19]. Exosomal miR-135b from chronic hypoxia multiple myeloma cells directly suppressed its target factor-inhibiting hypoxia inducible factor 1 (FIH-1) in endothelial cells and enhances the endothelial tube formation under hypoxia via the HIF-FIH signaling pathway [20]. Similarly, hypoxia can stimulate various miRNAs contain miR-210 overexpression in exosomes, so that promoting tumor angiogenesis [25].

The formation of premetastatic niche not only involves the angiogenesis and vascular permeability, but also the metabolic reprogramming and stromal reprogramming to facilitate tumor metastasis. Breast cancer can secret miR-122 enriched vesicles, which have been proved associated with breast cancer metastasis [26]. It can be taken up by the recipient premetastatic niche stromal cells such as astrocytes and lung fibroblasts to downregulate the glucose metabolism by decreasing the glycolytic enzyme pyruvate kinase (PKM) and glucose transporter 1 (GLUT1) [27]. Due to the availability of nutrient for the upcoming tumor cells, this new mechanism may be more important at an early stage prior to cancer-induced angiogenesis. What is more, EVs, rich in miR-494 and miR-542-3p, accelerate the premetastatic niche formation by targeting cadherin-17 and overexpressing the MMP2 and MMP3 in premetastatic lung stromal cells [28]. Transfection with a large amount of exosomal miRNAs (miR-100-5p, miR-21-5p, and miR-139-5p) in normal prostate stromal cells upregulated the production and release of VEGF [35, 36]. Integrin β1/α5/JNK/c-JUN signaling pathway participates in highermatrix stiffness, which is induced LOXL2 increasing in liver cancer cells. LOXL2 promotes the production of fibrin, the expression of MMP9 and CXCL12, and the recruitment of BMDCs to help the formation of premetastatic niche [37]. In PDAC, exosome derived protein MIF can induce the formation of hepatic premetastatic niche and enhance the expression of liver metastatic. LncRNA Sox2ot regulate Sox2 expression to promote epithelial-mesenchymal transformation (EMT) and stem cell-like properties by competitively binding the miR-200 family [38]. Thereby, it promotes the invasion and metastasis of PDAC. The researchers from the University of Wisconsin School of medicine and public health hypothesized that anaplastic thyroid carcinoma (ATC) cancer stem-like cells (CSC) secrete LncRNAs transferred by exosome. It is important that lnc-ROR induces EMT and establishes premetastatic niche [39] (Table 1).

3.3. CircRNAs. CircRNAs were once thought to be RNA splicing errors. However, they have now been shown to exist in many eukaryotic transcripts [40]. CircRNAs are mainly reported as miRNA sponges that affect downstream miRNAs target genes, regulate selective splicing, and affect host gene transcription [41]. Among circRNAs studies, miR-7 is the most studied miRNAs, which regulates multiple functions in the process of cancer, such as cell development, proliferation, and apoptosis [42].

The presence of circRNAs in exosomes was confirmed in cancer cell lines of hepatocellular carcinoma, colon cancer, lung cancer, gastric cancer, breast cancer, and cervical cancer. But circRNAs have not been reported in premetastatic niches.

3.4. Cross Talking. MiRNAs, LncRNAs, and circRNAs all have mutual regulation relationships, forming a cross talking network. NcRNAs and miRNAs can form a well-regulated interaction network [43]. It is well known that miRNAs play a role by targeting the 3 UTR of mRNAs [44]. LncRNAs-miRNAs interaction is like that of miRNAs-miRNAs. LncRNAs can bind to multiple miRNAs, and one mRNA can be targeted by multiple LncRNAs [45].
Table 1: Recently reported ncRNAs-mediated adaptations in a premetastatic niche.

| ncRNAs species | Cancer type | Biological function | Mechanism | Refs |
|----------------|-------------|---------------------|-----------|------|
| miRNA          | miR-9       | melanoma            | promote migration and angiogenesis | target to SOCS5 and activating JAK-STAT signaling pathway | [24] |
|                | miR-16, miR-21, miR-29a | lung cancer | promote tumor growth and metastasis | bind with TLR, trigger TLR-mediated pro-metastatic inflammatory response | [30] |
|                | miR-92a     | leukemia            | regulate endothelial gene expression | Downregulate target gene integrin α5, play a similar role in endogenous miRNAs in HUVECs | [19] |
|                | miR-100-5p, miR-21-5p, miR-139-5p | prostate cancer | modify pre-metastatic niche | increase MMP2, 9, 13, RANKL and fibroblast migration | [29] |
|                | miR-105     | breast cancer       | promote metastasis | destroy the vascular barriers by downregulating ZO-1 | [21] |
|                | miR-122     | breast cancer       | induce angiogenesis | downregulate the glucose metabolism by decreasing PKM and GLUT1 | [26] |
|                | miR-133b    | multiple myeloma    | enhance endothelial tube formation under hypoxia | suppress FHI-1 in endothelial cells via the HIF-FIH signaling pathway | [20] |
|                | miR-181c    | brain-metastatic breast cancer | facilitate migration | downregulate PDGK1 in brain endothelial cells to trigger BBB destruction exosomes containing a high expression level of miR-210 | [22] |
|                | miR-210     | leukemia            | affect angiogenesis | target cdh-17 and over express MMP2 and MMP3 | [25] |
|                | miR-494, miR-542-3p | pancreatic adenocarcinoma | accelerate the pre-metastatic niche formation | up-regulate the VEGF, promote MMP9, CXCL12, and the recruitment of BMDCs regulate Sox2 expression by binding the miR-200 family competitively | [35–37] |
| lncRNA         | H19         | hepatocellular carcinoma | promote angiogenesis and intercellular adhesion | up-regulate the VEGF, promote MMP9, CXCL12, and the recruitment of BMDCs regulate Sox2 expression by binding the miR-200 family competitively | [38] |
| LncRNA Sox2ot  | Pancratic duct adenocarcinoma | promote the invasion and metastasis | up-regulate the VEGF, promote MMP9, CXCL12, and the recruitment of BMDCs regulate Sox2 expression by binding the miR-200 family competitively | [38] |
| LncRNA MALAT1, linc-ROR | anaplastic thyroid carcinoma | establish pre-metastatic niche | induce EMT | [39] |

MD et al. summarized four ways of interaction between lncRNAs and miRNAs. The first is that LncRNAs are precursor molecules of miRNAs, for example, the precursor of H19 encoding miR-675 [46]. The second is that miRNAs reduce the stability of lncRNAs. Yoon et al. reported that RNA binding protein HuR recruits let-7/Ago2 to degrade LncRNA-p21 [47]. Thirdly, LncRNAs compete with miRNAs. For instance, the antisense transcript of CDRI is almost completely complementary to miR-671 which can guide the degradation of the antisense transcript of CDRI by AGO2-dependent methods [48]. Finally, as a sponge of miRNAs, LncRNA X chromosome inactivated specific transcript (XIST), inhibited the expression of miR-499a and promoted the expression of B-cell lymphoma-2 (Bcl2) [49]. LncRNAs competitively bind to miRNAs as competitive endogenous RNA (ceRNA) [50].

CircRNAs have a sponge-isolating effect on miRNAs [51]. Cirs-7 (CDR1as) was found to isolate tumor suppressor miR-7 which inhibits EGF receptors in oncogenes such as IRS-1, IRS-2, and Raf in glioblastoma [52]. The ciRs-7/miR-7/miR-671 axis confirmed the significance of circRNAs entrapment on miRNA in cancer (Figure 2).

4. Clinical Utility of ncRNAs

4.1. TDMCs: A Source of Novel and Specific Biomarkers of Cancer. Early detection of reliable cancer biomarkers is critical to diagnosis. Ideally, biomarkers should be targeted to specific tumor types and detected noninvasive techniques prior to transfer. Tumor-derived exosomes are involved in the interstitial interaction between tumor cells and surrounding tissues and promote the development of malignant tumors.

Circulating miRNAs have great potential as a biomarkers. They bind to exosomes/microvesicles or protein complexes and are chemically stable to RNase activity and reproducible
Figure 2: Mechanism of premetastatic niche formation. Primary tumors prior modulate the premetastatic niche in preparation for tumor cell colonization even before their arrival. TDMCs have the functions of recruiting BMDCs, making the immune heterogeneity, altering the vasculature, and reprogramming. They create premetastatic niche as the signal transduction mediators. NcRNAs, one of TDMCs, are involved in the formation of premetastatic niche. MiRNAs, lncRNAs, and circRNAs are building a well-regulated interaction network by directly regulating with each other.

In addition to miRNAs, lncRNAs associated with tumor-derived exosomes are also attractive as potential biomarkers. LncRNA PCA3 (DD3) is an approved urinary biomarker and prebiopsy diagnosis of prostate cancer [59]. Elevated lncRNA ZFAS1 in serum exosomes of GC patients may represent a better biomarker for GC diagnosis [60]. In 2015, the plasma study of liver cancer patients found that lncRNA XL0C_014172 and LOCI49086 are potential biomarkers for liver cancer metastasis [61]. Furthermore, the release of the regulation of high specific expression of lncRNAs in tumor tissues can be used as targets for the treatment of cancer [62].

CircRNAs, which are stably expressed in exosomes, are promising candidates for cancer biomarkers. Many circRNAs exhibit tissue-specific and developmental stage-specific patterns. CircRNAs are also described as biomarkers of aging in Drosophila [63]. In gastric cancer, the abundance of Hsa_circ_002059 was low. It was also lower in cancer tissues and adjacent tissues [64]. Chen et al. found that circPVT1 was upregulated in gastric cancer. It was an independent prognostic indicator for overall survival and disease-free survival of gastric cancer patients. This finding suggests that circPVT1 is a new prognostic marker for gastric cancer [65].

in the blood. Rodriguez M et al. confirmed that miR-196a-5p and miR-501-3p were downregulated in prostate cancer samples by rt-qPCR analysis in an independent cohort study, suggesting that specific miRNAs in urinary exosomes may serve as a noninvasive biomarker for the diagnosis of prostate cancer [53]. A higher level of circulating miR-122 was detected in early breast cancer metastasis progression [54], and a lower level of miR-125b in serum circulating exosomes of advanced melanoma could be used as a predictive marker [55]. In addition, these EVs can be used for the detection of tumor metastasis. The exosomes of patients with metastatic sporadic melanoma were compared with familial melanoma or the unaffected control group, and higher expression levels of miR-17, miR-19a, miR-21, miR-126, and miR-149 were found [56]. Exosome miR-21 is associated with esophageal cancer recurrence and distant metastasis [57]. Fleming et al. demonstrated that evaluating miR-15b, miR-30d, miR-150, and miR-425 was more likely to predict melanoma recurrence than TNM staging [58].

In addition to miRNAs, lncRNAs associated with tumor-derived exosomes are also attractive as potential biomarkers.
4.2. Targeting ncRNAs in the Premetastatic Niche for Cancer Therapeutics

4.2.1. The Therapeutic Potential of ncRNAs. NcRNAs have been proved to play an important role in tumorigenesis, typing, metastasis, drug resistance, and therapeutic effect [66]. Hence, many ncRNAs can be targeted for tumor therapy. What needs to be further investigated is how to consume EV or block the uptake of EV in cancer patients [67]. Functional studies have confirmed that miRNAs dysfunction is the cause of many cancers. MiRNA mimics and miRNA-targeting molecules (antimiRs) show promise in preclinical development [68]. MiRNAs have also been used in studies to sensitize tumor cells to chemotherapy. MiR-375 cotransports cisplatin nanoparticles as a promising treatment for liver cancer [69]. The fact that most IncRNAs are carcinogenic and upregulated during cancer suggests the possibility of therapeutic intervention. The specificity of IncRNAs has been used to selectively kill tumor cells, providing a pathway for targeted therapy. In addition, gene therapy can be tried to deliver beneficial tumor suppressor IncRNAs [70]. As for circRNAs, inhibiting the relevant f-circRNAs may be a new therapeutic approach, especially in the fight against cancer drug resistance [71].

4.2.2. Therapeutic Target Groups of Specific ncRNAs. Before precise tumor treatment, it is very necessary to study the best miRNA candidates or miRNA targets for each disease. Recently, miR-CLIP seq technology can identify miRNA-mRNA association and sequencing [72]. The miR-CLIP capture technique can also identify the interaction between miRNAs and IncRNAs [73]. For example, the sponge effect of IncRNA H19 on mir106a upregulated the corresponding mRNA level [74]. In addition, it will be necessary to further understand the interaction between IncRNAs and circRNAs.

4.2.3. Small Interfering RNA (siRNA) Therapy. To date, miRNAs and small interference RNAs (siRNA) play an important role through RNAi mechanism and are widely used in gene therapy, especially in cancer therapy. The efficiency of siRNA depends on a number of factors, such as targeted sequences, end modification, and whole-body delivery methods [75]. One of the most commonly used methods to inhibit the upregulation of carcinogenic IncRNAs is to deliver siRNA to target cells. Furthermore, IncRNAs expression was inhibited by the use of antisense oligonucleotide (ASO) or small molecule inhibitors [76]. Among them, some are undergoing Phase III clinical trials in prostate cancer, so far; however, most are still in the period of basic research [77].

4.2.4. NcRNAs Replacement Therapy. One is the use of antimiRs, common inhibitors AntigomiRs, locked nucleic acid (LNA), etc., to block the expression of miRNAs targeting mRNA in tumor and premetastatic niche [78]. MiR-15a and miR-16-1 provide indications for miRNA-based treatment, and strong regulation of clonal amplification of CLL plays a role at the level of mature leukemia [79]. AntimiRs targeting miR-122 have reached phase II clinical trials for hepatitis [80]. MiR-10b antagonists inhibit the metastasis of breast cancer in mice by silencing endogenous miR-10b, which is well tolerated in animals and is a promising candidate for the development of new antimetastatic drugs [81].

The second is the use of miRNAs mimics, which are a new therapeutic approach. In order to protect miRNAs from degradation by serum nucleases, miRNAs mimics were specifically delivered to tumor interested miRNAs by using the nanoparticle delivery system [82, 83]. For example, MiR-125b was directly injected into subcutaneous tumors using a nonviral vector composed of cationic polymer polyethylenimine (PEI), targeting VE-cadherin to induce nonfunctional angiogenesis and inhibit tumor growth [84]. MiR-34, an analogue of tumor suppressor, has reached stage I clinical trials for the treatment of cancer [85]. Other ncRNAs have not been explored for their functional regulation.

AntimiRs drugs combined with chemotherapy or targeted therapeutic drugs (such as small molecules or antibodies) are used to reduce miRNAs, potential checkpoint inhibitors, and to reduce adverse reactions. Therefore, further studies are needed to resolve some controversial issues to achieve the clinical application of exosomes in the microenvironment of premetastatic niche.

5. Conclusions and Perspective

From traditional therapy to molecular targeted therapy, great progress has been made in the treatment of primary tumors. However, for the treatment of the formation of premetastatic niche, how to identify and kill the premetastatic niche at an early stage, and how to avoid the toxic and off-target effects of ncRNAs drugs targeted premetastatic niche need to be solved urgently.

As one of TDMCs, ncRNAs has been confirmed to be involved in the formation of premetastatic niche. By understanding the formation mechanism of premetastatic niche through TDMCs, especially ncRNAs, the hypothesis of premetastatic niche is further studied, which may provide new strategies for us to develop new targeted antitumor drugs, thus greatly improving the therapeutic effect and prognosis of tumors. In this regard, siRNA therapy and ncRNAs replacement therapy through exosomes are promising strategies with initial results, while the physiological and pathological effects of exosomes such as IncRNAs and circRNAs in the premetastatic niche still need to be further studied. Moreover, the latest miR-CLIP seq technology and miR-CLIP capture technology recognize the association between miRNAs and mRNAs, miRNAs and IncRNAs, respectively. The cross talking of miRNAs with circRNAs, IncRNAs, and circRNAs is for further study. In the future, identify the interactions between ncRNAs before performing precise tumor therapy, study the optimal ncRNA candidates or ncRNA targets for each disease, and target inhibitors for their
interaction, which may provide the next generation of precise personalized drugs.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] Z. Wang and M. Zoller, "Exosomes, metastases, and the miracle of cancer stem cell markers," Cancer and Metastasis Reviews, 2019.

[2] S. Paget, "The distribution of secondary growths in cancer of the breast," The Lancet, vol. 133, no. 3421, pp. 571–573, 1889.

[3] Y. Guo, X. Ji, and J. Liu, "Effects of exosomes on pre-metastatic niche formation in tumors," Molecular Cancer, vol. 18, no. 1, p. 39, 2019.

[4] L. Nogués, A. Benito-Martín, M. Hergueta-Redondo, and H. Peinado, "The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination," Molecular Aspects of Medicine, vol. 37–43, 2017.

[5] Y. Liu and X. Cao, "Characteristics and significance of the pre-metastatic niche," Cancer Cell, vol. 30, no. 5, pp. 668–681, 2016.

[6] B. Darvishi, K. Majidzadeh-A, R. Ghadirian, M. Mosayebzadeh, and L. Farahmand, "Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies," Life Sciences, vol. 217, pp. 34–40, 2019.

[7] A. C. Panda, K. Abdelmohsen, and M. Gorospe, "SASP regulation by noncoding RNA," Mechanisms of Ageing and Development, vol. 168, pp. 37–43, 2017.

[8] Y. Xie, W. Dang, S. Zhang et al., "The role of exosomal noncoding RNAs in cancer," Molecular Cancer, vol. 18, no. 1, p. 37, 2019.

[9] B. Santosh, A. Varshney, and P. K. Yadava, "Non-coding RNAs: biological functions and applications," Cell Biochemistry and Function, vol. 33, no. 1, pp. 14–22, 2015.

[10] S. Diederichs, L. Bartsch, J. C. Berkmann et al., "The dark D. Ansel, K. M. Ansel, M. Bitzer et al., "The extracellular F. Fatima, K. Ekstrom, J. Nazarenko et al., "Non-coding RNAs in mesenchymal stem cell-derived extracellular vesicles: deciphering regulatory roles in stem cell potency, inflammatory resolve, and tissue regeneration," Front Genet, vol. 8, p. 161, 2017.

[11] Z. Wei, A. O. Batagov, S. Schinelli et al., "Coding and noncoding landscape of extracellular RNA released by human glioma stem cells," Nature Communications, vol. 8, p. 1145, 2017.

[12] J. Kaiser, "Malignant messengers," Science, vol. 352, no. 6282, pp. 164–166, 2016.

[13] R. Szatanek, M. Baj-Krzyworzeka, J. Zimoch, M. Lekka, M. Siedlar, and J. Baran, "The methods of choice for extracellular vesicles (evs) characterization," International Journal of Molecular Sciences, vol. 18, no. 6, p. 1153, 2017.

[14] J. H. Ohyashiki, T. Umezui, and K. Ohyashiki, "Exosomes promote bone marrow angiogenesis in hematologic neoplasia: The role of hypoxia," Current Opinion in Hematology, vol. 23, no. 3, pp. 268–273, 2016.

[15] T. Umezui, H. Tadokoro, K. Azuma, S. Yoshizawa, K. Ohyashiki, and J. H. Ohyashiki, "Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1," Blood, vol. 124, no. 25, pp. 3748–3757, 2014.

[16] H. Li, J. Liang, Y. Kuo et al., "miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer," Breast Cancer Research, vol. 19, no. 1, p. 133, 2017.

[17] N. Tominaga, N. Kosaka, M. Ono et al., "Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destroying blood-brain barrier," Nature Communications, vol. 6, p. 6716, 2015.

[18] F. Qi, T. He, L. Jia et al., "The miR-30 family inhibits pulmonary vascular hyperpermeability in the premetastatic phase by direct targeting of Skp2," Clinical Cancer Research, vol. 21, no. 13, pp. 3071–3080, 2015.

[19] S. J. Seashols-Williams, W. Budd, G. C. Clark et al., "MiR-9 acts as an OncomiR in prostate cancer through multiple pathways that drive tumour progression and metastasis," Plos One, vol. 11, no. 7, Article ID e0159601, 2016.

[20] X. Ma, J. Wang, J. Li et al., "Loading MiR-210 in endothelial progenitor cells derived exosomes boosts their beneficial effects on hypoxia/reoxygenation-injured human endothelial cells via protecting mitochondrial function," Cellular Physiology and Biochemistry, vol. 46, no. 2, pp. 664–675, 2018.

[21] I. X. Perez-Añorve, C. H. Gonzalez-DelaRosa, E. Soto-Reyes et al., "New insights into radioresistance in breast cancer identify a dual function of miR-122 as a tumor suppressor and oncomiR," Molecular Oncology, vol. 13, no. 5, pp. 1249–1267, 2019.

[22] M. Y. Fong, W. Zhou, L. Liu et al., "Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis," Nature Cell Biology, vol. 17, pp. 183–194, 2015.

[23] V. Chavali, S. C. Tyagi, and P. K. Mishra, "Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts," Cell Biochemistry and Biophysics, vol. 8, no. 1, pp. 25–35, 2014.

[24] C. A. Sanchez, E. I. Andahur, R. Valenzuela et al., "Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche," Oncotarget, vol. 7, no. 4, pp. 3993–4008, 2016.

[25] B. Pardini, D. De Maria, A. Francavilla et al., "MicroRNAs as markers of progression in cervical cancer: a systematic review," BMC Cancer, vol. 18, no. 1, p. 696, 2018.

[26] Y. Liu, Y. Gu, Y. Han et al., "Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar
epithelial TLR3 to recruit neutrophils," *Cancer Cell*, vol. 30, no. 2, pp. 243–256, 2016.

[32] U. H. Weidle, F. Birzle, G. Kollmorgen, and R. Rüger, "Long non-coding RNAs and their role in metastasis," *Cancer Genomics & Proteomics*, vol. 14, no. 3, pp. 143–160, 2017.

[33] H. J. Kim, K. J. Eoh, L. K. Kim et al., "The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer," *Oncotarget*, vol. 7, no. 50, pp. 83001–83016, 2016.

[34] R. Liu, X. Li, W. Zhu et al., "Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis," *Hepatology*, 2019.

[35] A. Conigliaro, V. Costa, A. Lo Dico et al., "CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 IncRNA," *Molecular Cancer*, vol. 14, no. 1, article no. 155, 2015.

[36] J. Zhang, C. Han, N. Ungerleider et al., "A novel TGF-β and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis," *Hepatology*, vol. 69, no. 4, pp. 1549–1563, 2019.

[37] S. Wu, Q. Zheng, X. Xing et al., "Matrix stiffness-upregulated LOXL2 promotes fibroenctin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation," *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 99, 2018.

[38] Z. Li, P. Jiang, J. Li et al., "Tumor-derived exosomal Inc-Sox20t promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma," *Oncogene*, vol. 37, no. 28, pp. 3822–3838, 2018.

[39] H. Hardin, H. Helein, K. Meyer et al., "Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of IncRNAs;* Laboratory Investigation*, vol. 98, no. 9, pp. 1133–1142, 2018.

[40] S. Qu, Y. Zhong, R. Shang et al., "The emerging landscape of circular RNA in life processes," *RNA Biology*, pp. 1–8, 2016.

[41] J. He, Q. Xie, H. Xu, J. Li, and Y. Li, "Circular RNAs and cancer," *Cancer Letters*, vol. 396, pp. 138–144, 2017.

[42] H. Li, X. Ma, and H. Li, "Intriguing circles: conflicts and controversies in circular RNA research," *Wiley Interdisciplinary Reviews: RNA*, p. e1538, 2019.

[43] W. Wang, Y. Su, S. Tang et al., "Identification of noncoding RNA expression profiles and regulatory interaction networks following traumatic spinal cord injury by sequence analysis," *Aging (Albany NY)*, vol. 11, no. 8, pp. 2352–2368, 2019.

[44] V. K. Mayya and T. F. Duchaine, "Ciphers and executioners: how 3′-untranslated regions determine the fate of messenger RNAs," *Frontiers in Genetics*, vol. 10, p. 6, 2019.

[45] Q. Wu, L. Guo, F. Jiang, L. Li, Z. Li, and F. Chen, "Analysis of the miRNA-miRNA-IncRNA networks in ER+ and ER- breast cancer cell lines," *Journal of Cellular and Molecular Medicine*, vol. 19, no. 12, pp. 2874–2887, 2015.

[46] L. L. Chen and J. C. Zhao, "Functional analysis of long noncoding RNAs in development and disease," *Advances in Experimental Medicine and Biology*, vol. 825, pp. 825–829, 2014.

[47] J. Yoon, K. Abdelmohsen, S. Srikantan et al., "LincRNA-p21 suppresses target miRNA translation," *Molecular Cell*, vol. 47, no. 4, pp. 648–655, 2012.

[48] D. Barbagallo, A. Condorelli, M. Ragusa et al., "Dysregulated miR-671-5p/CDRI-AS/CDRI/VSNL1 axis is involved in glioblastoma multiforme," *Oncotarget*, vol. 7, no. 4, pp. 4746–4759, 2016.

[49] Y. Zhang, X. Li, Y. Hou et al., "The IncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancer," *Acta Pharmacologica Sinica*, vol. 38, no. 3, pp. 371–438, 2017.

[50] R. Yang, L. Xing, M. Wang et al., "Comprehensive analysis of differentially expressed profiles of IncRNAs/miRNAs and miRNAs with associated ceRNA networks in triple-negative breast cancer," *Cellular Physiology and Biochemistry*, vol. 50, no. 2, pp. 473–488, 2018.

[51] E. Anastasiadou, A. Faggioni, P. Trivedi et al., "The nefarious nexus of noncoding RNAs in cancer," *International Journal of Molecular Sciences*, vol. 19, no. 7, p. 2072, 2018.

[52] T. B. Hansen, J. Kjems, and C. K. Damgaard, "Circular RNA and miR-7 in cancer," *Cancer Research*, vol. 73, no. 18, pp. 5609–5612, 2013.

[53] M. Rodriguez, C. Bajo-Santos, N. P. Hessvik et al., "Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes," *Molecular Cancer*, vol. 16, no. 1, p. 156, 2017.

[54] M. Y. Fong, W. Zhou, L. Liu et al., "Breast-cancer-secreted miR-122 reprograms glucose metabolism in pre-metastatic niche to promote metastasis," *Nature Cell Biology*, vol. 17, no. 2, pp. 183–194, 2015.

[55] V. Huber, V. Vallacchi, V. Fleming et al., "Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma," *The Journal of Clinical Investigation*, vol. 128, no. 12, pp. 5505–5516, 2018.

[56] S. Pfeffer, K. Grossmann, P. Cassidy et al., "Detection of exosomal miRNAs in the plasma of melanoma patients," *Journal of Clinical Medicine*, vol. 4, no. 12, pp. 2012–2027, 2015.

[57] Z. Gao, H. Liu, Y. Shi, L. Yin, Y. Zhu, and R. Liu, "Identification of cancer stem cell molecular markers and effects of hsa-miR-21-3p on stemness in esophageal squamous cell carcinoma," *Cancers*, vol. 11, no. 4, p. 518, 2019.

[58] N. H. Fleming, J. Zhong, I. P. da Silva et al., "Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients," *Cancer*, vol. 121, no. 1, pp. 51–59, 2015.

[59] A. A. Yarmishyn and I. V. Kurochkin, "Long noncoding RNAs: a potential novel class of cancer biomarkers," *Frontiers in Genetics*, vol. 6, p. 145, 2015.

[60] L. Pan, W. Liang, M. Fu et al., "Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression," *Journal of Cancer Research and Clinical Oncology*, vol. 143, no. 6, pp. 991–1004, 2017.

[61] J. Tang, R. Jiang, L. Deng, X. Zhang, K. Wang, and B. Sun, "Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma," *Oncotarget*, vol. 6, no. 6, pp. 4505–4515, 2015.

[62] A. Giakountis, P. Moulos, V. Zarkou et al., "A positive regulatory loop between a wt-regulated non-coding RNA and ASCL2 controls intestinal stem cell fate," *Cell Reports*, vol. 15, no. 12, pp. 2588–2596, 2016.

[63] M. Cortés-López, M. R. Gruner, D. A. Cooper et al., "Global accumulation of circRNAs during aging in Caenorhabditis elegans," *MBMC Genomics*, vol. 19, no. 1, p. 8, 2018.

[64] P. Li, S. Chen, H. Chen et al., "Using circular RNA as a novel type of biomarker in the screening of gastric cancer," *Clinica Chimica Acta*, vol. 444, pp. 132–136, 2015.

[65] J. Chen, Y. Li, Q. Zheng et al., "Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer," *Cancer Letters*, vol. 388, pp. 208–219, 2017.
[66] H. Sang, H. Liu, P. Xiong, and M. Zhu, "Long non-coding RNA functions in lung cancer," *Tumor Biology*, vol. 36, no. 6, pp. 4027–4037, 2015.

[67] R. Kalluri, "The biology and function of exosomes in cancer," *The Journal of Clinical Investigation*, vol. 126, no. 4, pp. 1208–1215, 2016.

[68] R. Rupaimoole and F. J. Slack, "MicroRNA therapeutics: towards a new era for the management of cancer and other diseases," *Nature Reviews Drug Discovery*, vol. 16, no. 3, pp. 203–222, 2017.

[69] T. Yang, P. Zhao, Z. Rong et al., "Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-loaded with microRNA-375," *Theranostics*, vol. 6, no. 1, pp. 1–15, 2016.

[70] M. K. Tripathi, K. Doxtater, F. Keramatnia et al., "Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes," *Drug Discovery Therapy*, vol. 23, no. 9, pp. 1635–1643, 2018.

[71] L. M. Holdt, A. Kohlmaier, and D. Teupser, "Molecular roles and function of circular RNAs in eukaryotic cells," *Cellular and Molecular Life Sciences*, vol. 75, no. 6, pp. 1071–1098, 2018.

[72] A. Ahadi, G. Sablok, and G. Hutvagner, "miRTar2GO: A novel rule-based model learning method for cell line specific microRNA target prediction that integrates Ago2 CLIP-Seq and validated microRNA-target interaction data," *Nucleic Acids Research*, vol. 45, no. 6, p. e42, 2016.

[73] M. Cao, J. Zhao, and G. Hu, "Genome-wide methods for investigating long noncoding RNAs," *Biomedicine & Pharmacotherapy*, vol. 111, pp. 395–401, 2019.

[74] J. Imig, A. Brunschweiger, A. Brümmer et al., "miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction," *Nature Chemical Biology*, vol. 11, no. 2, pp. 107–114, 2015.

[75] X. Zhong, D. Zhang, M. Xiong, and L. Zhang, "Noncoding RNA for cancer gene therapy," *Recent Results in Cancer Research*, vol. 209, pp. 51–60, 2016.

[76] J. Chery, "RNA therapeutics: RNAi and antisense mechanisms and clinical applications," *Postdoc Journal*, vol. 4, no. 7, pp. 35–50, 2016.

[77] C. Song, H. Chen, and C. Song, "Research status and progress of the RNA or protein biomarkers for prostate cancer," *Onco-Targets and Therapy*, vol. 12, pp. 2123–2136, 2019.

[78] B. Duygu, R. Juni, L. Ottaviani et al., "Comparison of different chemically modified inhibitors of miR-199b in vivo," *Biochemical Pharmacology*, vol. 159, pp. 106–115, 2019.

[79] G. Cutrona, S. Matis, M. Colombo et al., "Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy," *Leukemia*, vol. 31, no. 9, pp. 1894–1904, 2017.

[80] S. Thakral and K. Ghoshal, "miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir," *Current Gene Therapy*, vol. 15, no. 2, pp. 142–150, 2015.

[81] B. Yoo, A. Kavishwar, P. Wang et al., "Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer," *Scientific Reports*, vol. 7, no. 1, Article ID 45060, 2017.

[82] H. Mollaei, R. Safaralizadeh, and Z. Rostami, "MicroRNA replacement therapy in cancer," *Journal of Cellular Physiology*, vol. 234, no. 8, pp. 1–16, 2019.

[83] M. Skála, B. Flanoušková, L. Skálová, and P. Matoušková, "MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity," *Archives of Toxicology*, vol. 93, no. 1, pp. 1–9, 2019.